市場調查報告書
商品編碼
1373714
伴侶動物診斷服務全球市場規模、佔有率、產業趨勢分析報告:2023-2030 年按類型、動物類型、測試類別、地區分類的展望與預測Global Companion Animal Diagnostic Services Market Size, Share & Industry Trends Analysis Report By Type (Point-of-Care and Laboratory-based), By Animal Type, By Testing Category, By Regional Outlook and Forecast, 2023 - 2030 |
到2030年,伴侶動物診斷服務市場規模預計將達到 104 億美元,預測期內年複合成長率為 7.4%。
根據 KBV Cardinal 矩陣中發布的分析,Thermo Fisher Scientific Inc. 是市場上的領先者。 Zoetis, Inc.、Fujifilm Holdings Corporation 和 IDEXX Laboratories, Inc. 等公司是市場上的主要創新者。2022年12月,FUJIFILM Holdings收購了Inspirata, Inc.,將病理影像和資料整合到醫療機構的電子健康記錄系統中。此外,此次收購有助於簡化腫瘤患者的定向治療。
市場成長要素
診斷技術的進步
數位放射線照相、超音波、基因檢測和 PCR 檢測等診斷技術的進步提高寵物診斷服務的準確性和範圍。數位X 光技術已在很大程度上取代了傳統的基於膠片的 X 光攝影。現在可以實現更清晰、更快速的成像,減少動物和工作人員的輻射暴露,並且現在可以輕鬆地與專家共用影像以進行遠端諮詢。超音波技術的進步也使得以高解析度和細節對軟組織和器官進行成像成為可能。 電腦斷層掃描和 MRI 掃描提供極其清晰的3D影像,可以幫助診斷神經系統疾病、腫瘤和肌肉骨骼損傷等複雜疾病。診斷技術的這些進步提高伴侶動物的護理品質,並擴大獸醫醫院提供的服務範圍。隨著技術的發展,診斷能力預計將變得更加複雜,有助於市場的進一步改善。
寵物健康意識不斷增強
寵物飼主越來越意識到預防性動物保健和早期發現疾病的重要性。這種意識是尋求寵物診斷服務的驅動力。了解定期檢查和疫苗接種重要性的飼主更有可能安排定期去看獸醫。這些訪問通常包括診斷測試作為體檢的一部分。具知識的飼主知道,及早發現疾病可以為寵物帶來更有效的治療和更好的結果。這些飼主更有可能要求對常見健康問題進行診斷測試和篩檢。此類方法通常包括診斷測試以指南治療計劃。提高寵物健康意識將有利於市場並提高寵物的壽命和福祉。隨著人們意識的不斷增強,對診斷服務的需求可能會保持強勁,並進一步推動市場進步。
市場抑制因素
診斷服務費用高
對於一些寵物主人來說,某些診斷測試和程序的費用可能令人望而卻步,尤其是那些經濟能力較差的飼主。這可能會導致延遲接受必要的獸醫護理和診斷。高昂的診斷費用阻礙了飼主投資於定期檢查和篩檢等預防性護理。結果,錯過了早期疾病發現和早期療育的機會。在農村地區和獸醫服務有限的地區,診斷費用可能是寵物醫療保健的主要障礙。寵物飼主必須遠距才能獲得廉價的服務。因此,診斷服務的高成本對市場構成重大挑戰。
依類型分類的展望
依類型分類,服務市場分為現場護理(POC)類型和實驗室類型。2022年,即時護理(POC)領域佔據市場最大的銷售佔有率。 POC 領域與遠端醫療平台相連,讓獸醫可以遠端諮詢寵物飼主,同時使用 POC 診斷評估動物的健康狀況。 POC 診斷有助於通用感染疾病監測,並透過快速識別伴侶動物中的潛在病例,為公共衛生配合措施做出貢獻。 POC 產業的成長是由於伴侶動物醫療保健領域對方便、快速的現場診斷解決方案的需求不斷成長而推動的。
動物物種展望
根據動物類型,市場分為狗、貓、馬等。 貓細分市場2022年在市場中取得了顯著的收益佔有率。貓的壽命越來越長,老年貓的數量也在增加。這個年齡層需要更頻繁的診斷評估,以管理與老齡化相關的健康問題,如腎臟病和關節炎。腸道蠕蟲和心臟病等寄生蟲的診斷測試對於貓的健康非常重要。隨著貓咪數量的增加,對預防性診斷服務的需求也增加。
測試類別的展望
依測試類別,市場分為臨床化學、微生物學、寄生蟲學、組織病理學、細胞病理學、血液學、免疫學/血清學、診斷影像、分子診斷等。2022年,臨床化學領域佔據市場最高收益佔有率。臨床化學測試通常用於評估伴侶動物的整體健康狀況和福祉。臨床化學測試為獸醫提供基線資料,以監測動物隨時間的健康狀況。臨床化學測試可以檢測伴侶動物是否有各種疾病和健康狀況。
區域展望
依地區分類,對北美、歐洲、亞太地區和拉丁美洲地區市場進行了分析。2022年,北美地區的收益佔有率最高,並引領市場。北美是世界上最大的市場之一。由於寵物數量的增加,寵物健康意識的提高,診斷技術的進步以及對寵物預防性保健的日益重視,市場持續成長。北美各地的獸醫醫院和診所提供各種診斷服務,包括血液檢查、尿液檢查、超音波檢查、超音波檢查和內視鏡檢查。這些設施為伴侶動物提供全面的照顧。在寵物飼養趨勢、先進的醫療保健實踐以及對寵物健康和福祉的高度關注的推動下,北美擁有強勁成長的市場。該地區處於獸醫診斷創新和實施的前沿。
The Global Companion Animal Diagnostic Services Market size is expected to reach $10.4 billion by 2030, rising at a market growth of 7.4% CAGR during the forecast period.
Cytopathology is performed in real-time during procedures. This immediate feedback aids veterinarians in making on-the-spot decisions about patient care. Thus, the cytopathology segment garnered $342.6 million revenue in the market in 2022. Cytopathology provides rapid results, often within minutes to hours, allowing veterinarians to diagnose and initiate treatment for companion animals quickly. This is particularly valuable in emergency cases and when prompt decisions are essential.
The major strategies followed by the market participants are Acquisitions as the key developmental strategy to keep pace with the changing demands of end users. For instance, In June, 2023, Mars, Inc. completed the acquisition of Heska Corporation. With this acquisition, Mars would achieve wider coverage across diagnostics and technology, better R&D and access to pet healthcare solutions. Additionally, In September, 2022, Zoetis Inc. completed the acquisition of Jurox Pty Limited, an Australian veterinary pharmaceutical manufacturer. Through this acquisition, Zoetis achieved greater worldwide expansion and the manufacture of an anaesthetic product for companion animals called Alfaxan.
Based on the Analysis presented in the KBV Cardinal matrix; Thermo Fisher Scientific Inc. is the forerunner in the Market. Companies such as Zoetis, Inc., Fujifilm Holdings Corporation, IDEXX Laboratories, Inc. are some of the key innovators in Market. In December, 2022, Fujifilm Holdings Corporation acquired Inspirata, Inc., to merge pathology images and data into the electronic health record system of the healthcare organizations. Additionally, the acquisition helped to simplify care designated for oncology patients.
Market Growth Factors
Advancements in diagnostic technologies
Ongoing advancements in diagnostic technologies, such as digital radiography, ultrasound, genetic testing, and PCR assays, have improved the accuracy and range of pet diagnostic services. Digital X-ray technology has largely replaced traditional film-based radiography. It provides clearer and faster imaging, reduces radiation exposure for animals and staff, and allows for easy sharing of images with specialists for remote consultation. Ultrasound technology has advanced, offering higher resolution and better detail for imaging soft tissues and organs. CT and MRI scans provide three-dimensional images with exceptional clarity, aiding in diagnosing complex conditions such as neurological disorders, tumors, and musculoskeletal injuries. These advancements in diagnostic technologies have enhanced the quality of care for companion animals and expanded the range of services that veterinary clinics offer. As technology evolves, diagnostic capabilities will likely become even more advanced, contributing to further improvements in market.
Rising awareness of pet health
Pet owners are becoming increasingly conscious of the significance of preventive care and early disease detection in their animals. This awareness drives them to seek diagnostic services for their pets. Pet owners who know the importance of regular checkups and vaccinations are more likely to schedule routine visits to veterinary clinics. These visits often include diagnostic tests as part of the wellness examination. Knowledgeable pet owners understand that early detection of diseases can lead to more effective treatments and better outcomes for their pets. They are more likely to request diagnostic tests and screenings for common health issues. These approaches often involve diagnostic tests to guide treatment plans. The rising awareness of pet health benefits the market and improves pet longevity and well-being. As this awareness grows, the demand for diagnostic services will likely remain strong, further driving advancements in market.
Market Restraining Factors
High cost of diagnostic services
The cost of certain diagnostic tests and procedures is prohibitive for some pet owners, especially those with limited financial resources. This can lead to delays in seeking necessary veterinary care and diagnostics. High diagnostic costs discourage pet owners from investing in preventive care, including regular checkups and screenings. This can result in missed opportunities for early disease detection and intervention. In rural or underserved areas, where veterinary services are less abundant, the cost of diagnostics can be a significant barrier to pet healthcare. Pet owners need to travel long distances to access affordable services. Therefore, the high costs of diagnostic services pose a significant challenge to the market.
Type Outlook
Based on type, the services market is classified into point-of-care (POC) and laboratory-based. In 2022, the point-of-care (POC) segment witnessed the largest revenue share in the market. The POC segment aligns with telemedicine platforms, allowing veterinarians to consult remotely with pet owners while using POC diagnostics to assess an animal's health condition. POC diagnostics aid in surveilling zoonotic diseases by quickly identifying potential cases in companion animals, thus contributing to public health efforts. The growth of the POC segment is driven by the increasing demand for convenient, rapid, on-site diagnostic solutions in companion animal healthcare.
Animal Type Outlook
On the basis of animal type, the market is divided into dogs, cats, horses, and others. The cats segment recorded a remarkable revenue share in the market in 2022. Cats are living longer, and the senior cat population is growing. This age group requires more frequent diagnostic assessments to manage age-related health concerns like kidney disease and arthritis. Diagnostic tests for parasites like intestinal worms and heartworms are essential for the health of cats. As the cat population increases, so does the demand for preventive diagnostic services.
Testing Category Outlook
By testing category, the market is categorized into clinical chemistry, microbiology, parasitology, histopathology, cytopathology, hematology, immunology & serology, imaging, molecular diagnostics, and others. In 2022, the clinical chemistry segment held the highest revenue share in the market. Clinical chemistry tests are routinely used to assess companion animals' overall health and well-being. They provide baseline data veterinarians use to monitor an animal's health over time. Clinical chemistry tests can detect the presence of various diseases and health conditions in companion animals.
Regional Outlook
Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, North America led the market by generating the highest revenue share. North America has one of the largest markets globally. The market continues to grow due to increasing pet ownership, rising awareness of pet health, advancements in diagnostic technologies, and a growing emphasis on preventive healthcare for pets. Veterinary clinics and hospitals across North America offer various diagnostic services, including blood tests, urinalysis, radiology, ultrasonography, and endoscopy. These facilities provide comprehensive care for companion animals. North America boasts a robust and growing market, driven by pet ownership trends, advanced healthcare practices, and a strong emphasis on pet health and well-being. This region remains at the forefront of veterinary diagnostics innovation and adoption.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Zoetis, Inc., IDEXX Laboratories, Inc., Mars Inc., Fujifilm Holdings Corporation, Embark Veterinary, Inc., Thermo Fisher Scientific Inc., Patterson Companies, Inc., Randox Laboratories Limited, CVS Group Plc, and Neogen Corporation
Recent Strategies Deployed in Companion Animal Diagnostic Services Market
Partnerships, Collaborations, and Agreements:
Apr-2023: Thermo Fisher Scientific Inc. partnered with ALPCO-GeneProof, a global leader in immunodiagnostics and molecular diagnostics. Through this partnership, the TaqPath Menu | GeneProof PCR kits were introduced into the market, which strengthened the supply chains and the support systems of Thermo Fisher.
Jan-2023: Thermo Fisher Scientific Inc. formed a partnership with AstraZeneca, a British-Swedish multinational pharmaceutical and biotechnology company. Under this partnership, a solid tissue and blood-based companion diagnostic (CDx) test for Tagrisso (osimertinib) was launched which would ease the treatment of patients with non-small cell lung cancer (NSCLC).
Oct-2022: CVS Group plc came into a partnership with Provet Cloud, an easy-to-use cloud-based veterinary practice management software. With this Partnership, CVS Group bettered its operations through Provet Cloud's large-scale implementations and open software infrastructure.
Jul-2020: Thermo Fisher Scientific Inc. signed an agreement with Chugai Pharmaceutical Co., Ltd., a drug manufacturer operating in Japan. With this agreement, the use of the Oncomine Dx Target Test was expanded in Japan.
Product Launches and Product Expansions:
Aug-2023: Neogen Corporation Launched Igenity Enhanced Dairy, a progressive genome data management tool. Igenity Enhanced Dairy is a digital service helping dairy producers to improve their mating decisions.
Jun-2023: Neogen Corporation introduced My CatScan 2.0, facilitating genetic screening in cats. My CatScan 2.0 provides simplified experience through the utilization of a simple cheek swab method and offers data in case of over 120 genetic health conditions.
May-2023: Neogen Corporation released two assays, Reveal for Histamine and Reveal Q+ for Histamine, which help in histamine detection. Reveal and Reveal Q+ assays use water extraction method to provide results quickly, prevent disposition of chemicals and reduce the testing time.
Sep-2022: Neogen Corporation unveiled Encompass platform, for accelerating genomic results management and visualization. The Encompass platform empowers Igenity users to regulate their data and increase the benefits of genome testing.
Acquisition and Mergers:
Jun-2023: Mars, Inc. completed the acquisition of Heska Corporation, engaged in developing medical devices to improve the quality of pet care. With this acquisition, Mars would achieve wider coverage across diagnostics and technology, better R&D and access to pet healthcare solutions.
Dec-2022: Fujifilm Holdings Corporation acquired Inspirata, Inc., a leading provider of AI-NLP powered oncology informatics solutions. Through this acquisition, Fujifilm developed its Synapse Enterprise Imaging thus helping to merge pathology images and data into the electronic health record system of the healthcare organisations. Additionally, the acquisition helped to simplify care designated for oncology patients.
Sep-2022: Zoetis Inc. completed the acquisition of Jurox Pty Limited, an Australian veterinary pharmaceutical manufacturer. Through this acquisition, Zoetis achieved greater worldwide expansion and the manufacture of an anaesthetic product for companion animals called Alfaxan.
Sep-2022: Zoetis, Inc. took over NewMetrica, a developer of instruments to measure the quality of life in animals. Through this acquisition, Zoetis strengthened its capabilities and magnified expertise in quality-of-life assessments for the betterment of well-being of animals.
Jun-2022: Zoetis Inc. acquired Basepaws Inc., a petcare genetics company. Under the acquisition, Zoetis upgraded its portfolio in precision animal health and created its future roadmap towards innovations in petcare.
Jun-2021: IDEXX Laboratories, Inc. took over ezyVet, a cloud-based Practice Management software. Through this acquisition, IDEXX broadened its cloud software products that helped customers to raise the standard of care provided to the patients, improve efficiency and communications with the pet owners.
Sep-2021: Neogen Corporation took over CAPInnoVet, Inc., a fast-growing companion animal products company. Through this acquisition, Neogen paved its roadmap into the parasiticide market and improved its position within the Animal Safety business segment.
Jan-2021: Neogen Corporation acquired Megazyme, Ltd., a world leader in the development of biochemical assay kits. With this acquisition, Neogen bettered its relationship with the food producers and companies operating in the food security and quality business.
Market Segments covered in the Report:
By Type
By Animal Type
By Testing Category
By Geography
Companies Profiled
Unique Offerings from KBV Research